Inactief instrument

Andere talen Cytosorbents Corp OTC Bulletin Board

Aandelen

CTSO

US23283X1072

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting	05/06
CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract	04/06
Earnings Flash (CTSO) CYTOSORBENTS Posts Q1 Revenue $9.8M, vs. Street Est of $9.79M	09/05
CytoSorbents: Q1 Earnings Snapshot	09/05
CytoSorbents Reports First Quarter 2024 Results	09/05
Cytosorbents Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe	02/05
CytoSorbents to Report First Quarter 2024 Operating and Financial Results	26/04
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting	17/04
Cytosorbents Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	15/03
Earnings Flash (CTSO) CYTOSORBENTS Reports Q4 Revenue $8.7M, vs. Street Est of $9.8M	14/03
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results	14/03
CytoSorbents to Report Fiscal 2023 Operating and Financial Results	06/03
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference	08/02
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference	08/02
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO	31/01
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO	23/01
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients	17/01
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients	17/01
Cytosorbents Corporation Reports Excellent Outcomes from A Groundbreaking Randomized Controlled Trial Using Cytosorb® Blood Purification During Heart Transplant, Recently Published in the European Society of Cardiology Journal, Esc Heart Failure	17/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cytosorbents Corp OTC Bulletin Board

Aandelen

CTSO

US23283X1072

Andere talen

Filters